Capstone Therapeutics Corp. Form SC 13G/A February 17, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 7)1

Capstone Therapeutics Corp. (Name of Issuer)

Common Stock, par value \$0.0005 per share (Title of Class of Securities)

14068E109 (CUSIP Number)

December 31, 2014 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP NO. 14068E109

1	NAME OF REPORTING PERSON			
2	Biotechnology Value Fund, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP SEC USE ONLY (a) x (b) o			
4			ORGANIZATION	
	Delaware			
NUMBER OF SHARES		5	SOLE VOTING POWER	
BENEFICIALLY OWNED BY		6	0 shares SHARED VOTING POWER	
EACH REPORTING PERSON WITH		7	1,619,888 SOLE DISPOSITIVE POWER	
		8	0 shares SHARED DISPOSITIVE POWE	R
9	AGGREGATE	AMOUNT BEN	1,619,888 EFICIALLY OWNED BY EACH	REPORTING PERSON
10		F THE AGGREC ERTAIN SHARE	GATE AMOUNT IN ROW (9)	
11	PERCENT OF	CLASS REPRES	SENTED BY AMOUNT IN ROW	(9)
12	4.0% TYPE OF REPO	ORTING PERSC	DN	
	PN			
2				

NAME OF REPORTING PERSON

CUSIP NO. 14068E109

1	TVINL OF KE	ORTHOTERS		
2	Biotechnology Value Fund II, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A (a) x			
3	GROUP SEC USE ONL	ĽΥ		(b) o
4	CITIZENSHIP	OR PLACE OF 0	ORGANIZATION	
	Delaware			
NUMBER OF SHARES		5	SOLE VOTING POWER	
BENEFICIALLY	7		0 shares	
OWNED BY		6	SHARED VOTING POWER	
EACH REPORTING			996,200	
PERSON WITH		7	SOLE DISPOSITIVE POWER	
		8	0 shares SHARED DISPOSITIVE POWE	D
		o	SHARED DISTOSITIVE TOWE	K
			996,200	
9	AGGREGATE	AMOUNT BEN	EFICIALLY OWNED BY EACH	REPORTING PERSON
	996,200			
10	CHECK BOX		GATE AMOUNT IN ROW (9)	
	EXCLUDES C	ERTAIN SHARE	ES	
11	PERCENT OF	CLASS REPRES	SENTED BY AMOUNT IN ROW	(9)
12	2.4%	ORTING PERSC	NNI	
12	I I PE OF REP	ORTING PERSC	JIN .	
	PN			
3				

CUSIP NO. 14068E109

1	NAME OF REI	PORTING PERS	ON		
2	BVF Investments, L.L.C. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o				
3	SEC USE ONL	λY			
4	CITIZENSHIP	OR PLACE OF	ORGANIZATION		
	Delaware				
NUMBER OF SHARES	Delaware	5	SOLE VOTING POWER		
BENEFICIALLY	•		0 shares		
OWNED BY		6	SHARED VOTING POWER		
EACH					
REPORTING			3,993,637		
PERSON WITH		7	SOLE DISPOSITIVE POWER		
			0 shares		
		8	SHARED DISPOSITIVE POWE	D	
		O	SIT IKED DISTOSITIVE TOWE	IX.	
			3,993,637		
9	AGGREGATE	AMOUNT BEN	EFICIALLY OWNED BY EACH	REPORTING PERSON	
	3,993,637				
10			GATE AMOUNT IN ROW (9)	•	
	EXCLUDES C	ERTAIN SHARI	ES		
11	DED CENT OF	CI ACC DEDDES	SENTED BY AMOUNT IN ROW	(0)	
11	FERCENT OF	CLASS KEFKE	SENTED BY AMOUNT IN ROW	(9)	
	9.8%				
12		ORTING PERSO	ON		
	OO				
4					
4					

CUSIP NO. 14068E109

1	NAME OF REPORTING PERSON					
2 3	Investment 10, L.L.C. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (b) o SEC USE ONLY					
4	CITIZENSHIP	OR PLACE OF	ORGANIZATION			
NUMBER OF SHARES	Illinois	5	SOLE VOTING POWER			
BENEFICIALLY OWNED BY EACH		6	0 shares SHARED VOTING POWER			
REPORTING PERSON WITH		7	529,400 SOLE DISPOSITIVE POWER			
		8	0 shares SHARED DISPOSITIVE POWE	R		
9	AGGREGATE	AMOUNT BEN	529,400 EFICIALLY OWNED BY EACH	REPORTING PERSON		
10		IF THE AGGREC ERTAIN SHARE	GATE AMOUNT IN ROW (9)			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
12	1.3% TYPE OF REP	ORTING PERSC	DN			
5						

NAME OF REPORTING PERSON

CUSIP NO. 14068E109

2				(a) x (b) o
4	CITIZENSHIP	OR PLACE OF	ORGANIZATION	
NUMBER OF SHARES	Delaware	5	SOLE VOTING POWER	
BENEFICIALLY OWNED BY EACH	•	6	0 shares SHARED VOTING POWER	
REPORTING PERSON WITH		7	616,563 SOLE DISPOSITIVE POWER	
		8	0 shares SHARED DISPOSITIVE POWE	ER.
9	AGGREGATE	AMOUNT BEN	616,563 EFICIALLY OWNED BY EACH	REPORTING PERSON
10		IF THE AGGREG ERTAIN SHARE	GATE AMOUNT IN ROW (9) ES	
11	PERCENT OF	CLASS REPRES	SENTED BY AMOUNT IN ROW	(9)
12	1.5% TYPE OF REP	ORTING PERSO	ON	
	OO			
6				

NAME OF REPORTING PERSON

CUSIP NO. 14068E109

2 3 4	GROUP SEC USE ONL	APPROPRIATE I	BOX IF A MEMBER OF A ORGANIZATION	(a) x (b) o
NUMBER OF SHARES	Delaware	5	SOLE VOTING POWER	
BENEFICIALLY OWNED BY EACH	•	6	0 shares SHARED VOTING POWER	
REPORTING PERSON WITH		7	7,755,688 SOLE DISPOSITIVE POWER	
		8	0 shares SHARED DISPOSITIVE POWE	CR
9	AGGREGATE	AMOUNT BEN	7,755,688 EFICIALLY OWNED BY EACH	REPORTING PERSON
10		IF THE AGGREG	GATE AMOUNT IN ROW (9) ES	
11	PERCENT OF	CLASS REPRES	SENTED BY AMOUNT IN ROW	(9)
12	19.0% TYPE OF REP	ORTING PERSO	DN	
	PN, IA			
7				

NAME OF REPORTING PERSON

CUSIP NO. 14068E109

2 3 4	BVF Inc. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION			* *
NUMBER OF	Delaware	5	SOLE VOTING POWER	
SHARES BENEFICIALLY OWNED BY EACH		6	0 shares SHARED VOTING POWER	
REPORTING PERSON WITH		7	7,755,688 SOLE DISPOSITIVE POWER	
		8	0 shares SHARED DISPOSITIVE POWE	R
9	AGGREGATE	AMOUNT BEN	7,755,688 EFICIALLY OWNED BY EACH	REPORTING PERSON
10		IF THE AGGREG ERTAIN SHARE	GATE AMOUNT IN ROW (9)	
11	PERCENT OF	CLASS REPRES	SENTED BY AMOUNT IN ROW	(9)
12	19.0% TYPE OF REP	ORTING PERSC	N	
	CO			
8				

NAME OF REPORTING PERSON

CUSIP NO. 14068E109

1	TVIIVIE OF THE	I ORTING I ERS		
2	Mark N. Lampert CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o			
3	SEC USE ONI	LY		
4	CITIZENSHIP	CITIZENSHIP OR PLACE OF ORGANIZATION		
	United States			
NUMBER OF SHARES		5	SOLE VOTING POWER	
BENEFICIALLY	?		0 shares	
OWNED BY EACH		6	SHARED VOTING POWER	
REPORTING			7,755,688	
PERSON WITH		7	SOLE DISPOSITIVE POWER	
			0 shares	
		8	SHARED DISPOSITIVE POWE	R
			7,755,688	
9	AGGREGATE	AMOUNT BEN	EFICIALLY OWNED BY EACH	REPORTING PERSON
	7,755,688			
10			GATE AMOUNT IN ROW (9)	
	EXCLUDES C	ERTAIN SHARI	ES	
11	PERCENT OF	CLASS REPRES	SENTED BY AMOUNT IN ROW	(9)
	19.0%			
12	TYPE OF REP	ORTING PERSO	ON	
	IN			
9				

CUSIP NO. 14068E109

Item 1(a). Name of Issuer:

Capstone Therapeutics Corp., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

1275 W. Washington Street

Suite 104

Tempe, AZ 85281

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

1 Sansome Street, 30th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

1 Sansome Street, 30th Floor San Francisco, California 94104

Citizenship: Delaware

BVF Investments, L.L.C. ("BVLLC") 900 North Michigan Avenue, Suite 1100

Chicago, Illinois 60611 Citizenship: Delaware

Investment 10, L.L.C. ("ILL10")

900 North Michigan Avenue, Suite 1100

Chicago, Illinois 60611

Citizenship: Illinois

MSI BVF SPV, LLC ("MSI")

c/o Magnitude Capital, LLC

601 Lexington Avenue, 59th Floor

New York, NY 10022

Citizenship: Delaware

BVF Partners L.P. ("Partners")

900 North Michigan Avenue, Suite 1100

Chicago, Illinois 60611

Citizenship: Delaware

BVF Inc.

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 1 Sansome Street, 30th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

CUSIP NO. 1	4068E109			
Item 2(d).			Title of Class of	f Securities:
Common Sto	ck, par value	\$0.0005 per sl	hare (the "Common Stock	.")
Item 2(e).			CUSIP No	umber:
14068E109				
Item 3. If This	s Statement i	s Filed Pursua	nt to Rule 13d-1(b), or 13	d-2(b) or (c), Check Whether the Person Filing is a:
			/x/	Not applicable.
(a	ı) .	// B	roker or dealer registered	under Section 15 of the Exchange Act.
	(b)	//	Bank as defined in	Section 3(a)(6) of the Exchange Act.
(c)	//	Insur	ance company as defined	in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment of	company registered under	Section 8 of the Investment Company Act.
(e	e)	// A	an investment adviser in a	accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	// An e	mployee benef	it plan or endowment fun	d in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	// A p	arent holding c	company or control persor	in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	// A	savings associ	ation as defined in Section	n 3(b) of the Federal Deposit Insurance Act.
	ch plan that nent Compan		om the definition of an i	nvestment company under Section 3(c)(14) of the
	(j)	//	Group, in acco	ordance with Rule 13d-1(b)(1)(ii)(J).
_			240.13d-1(b)(1)(ii)(K). If specify the type of institu	filing as a non-U.S. institution in accordance with ation:
Item 4.			Ownersh	nip
		(a)	Amo	unt beneficially owned:
As of the clo	ose of busine	ss on Decembe	er 31, 2014, (i) BVF bene	eficially owned 1,619,888 shares of Common Stock

As of the close of business on December 31, 2014, (i) BVF beneficially owned 1,619,888 shares of Common Stock, (ii) BVF2 beneficially owned 996,200 shares of Common Stock, (iii) BVLLC beneficially owned 3,993,637 shares of Common Stock (iv) ILL10 beneficially owned 529,400 shares of Common Stock and (v) MSI beneficially owned 616,563 shares of Common Stock.

CUSIP NO. 14068E109

Partners, as the general partner of BVF and BVF2, the manager of BVLLC and the investment adviser of ILL10 and MSI, may be deemed to beneficially own the 7,755,688 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, BVLLC, ILL10 and MSI.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 7,755,688 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 7,755,688 shares of Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, BVLLC ILL10, and MSI and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 40,885,411 shares of Common Stock outstanding as of October 31, 2014, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2014.

As of the close of business on December 31, 2014, (i) BVF beneficially owned approximately 4.0% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 2.4% of the outstanding shares of Common Stock, (iii) BVLLC beneficially owned approximately 9.8% of the outstanding shares of Common Stock, (iv) ILL10 beneficially owned approximately 1.3% of the outstanding shares of Common Stock, (v) MSI beneficially owned approximately 1.5% of the outstanding shares of Common Stock and (vi) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 19.0% of the outstanding shares of Common Stock.

(c)	Number of shares as to which such person has:
(i)	Sole power to vote or to direct the vote
	See Cover Pages Items 5-9.
(ii)	Shared power to vote or to direct the vote
	See Cover Pages Items 5-9.
(iii)	Sole power to dispose or to direct the disposition of
	See Cover Pages Items 5-9.
(iv)	Shared power to dispose or to direct the disposition of
	See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Pursuant to the operating agreement of BVLLC, Partners is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVLLC, in the shares of Common Stock and other securities of the Issuer and to vote, exercise or convert and dispose of each security, and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.

Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, BVLLC, ILL10 and MSI.

Item Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent 7. Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP NO. 14068E109

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2015

BIOTECHNOLOGY VALUE FUND, L.P.

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its general

By: BVF Partners L.P., its investment adviser

partner

By:

By:

By:

By: BVF Inc., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

/s/ Mark N. Lampert

Mark N. Lampert

BVF Partners L.P., its investment

President

President

BIOTECHNOLOGY VALUE FUND II, L.P.

MSI BVF SPV, LLC

By: BVF Partners L.P., its general

partner

adviser

By: BVF Inc., its general partner

By: BVF Inc., its general partner

/s/ Mark N. Lampert

By: /s/ Mark N. Lampert
Mark N. Lampert

Mark N. Lampert

President

President

BVF PARTNERS L.P.

BVF INC.

By:

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

/s/ Mark N. Lampert

Mark N. Lampert

Mark N. Lampert

President

President

/s/ Mark N. Lampert MARK N. LAMPERT

BVF INVESTMENTS, L.L.C.

By: BVF Partners L.P., its manager By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President